…cancer professionals – physicians, researchers and society execs – have felt uncomfortably complicit with a paradigm that too often extracts exorbitant sums of money for miniscule clinical benefit.
…striving for ever-higher earnings, drug companies large and small are relentlessly increasing pricing on old and new drugs because they can. They can because the industry successfully deployed lobbyists who persuaded a receptive Congress to heavily favor their interests, spinning laws away from regulatory controls and toward payment at any price. These circumstances, nurtured by pharma itself, make a 55-fold price increase possible and legal, if outrageous. And that’s the elephant in the room.
Brian Klepper Published 6/09/14 in Employee Benefit News One of America’s most enduring mysteries is why the organizations that pay for
Brian Klepper Posted 11/17/13 on Medscape Connect’s Care and Cost Blog Recently I was asked to intervene on behalf of a patient
Brian Klepper http://email@example.comQ5Savfkkqo@.2a59c1b3!comment=1 Posted 10/10/12 on Medscape Connect’s Care & Cost Blog When an employer sits down with his health care
Brian Klepper Published in the Columbus, GA Ledger-Enquirer on Sunday, 9/15/13 I recently was privileged to deliver a keynote at
David Harlow Posted August 13, 2013 on HealthBlawg Recently, there were a couple of breathless articles about the RUC (Relative